PowerPoint 프레젠테이션

Size: px
Start display at page:

Download "PowerPoint 프레젠테이션"

Transcription

1 ViroMed R&D IR Day Global Leader in DNA Gene Medicine #1

2 제품및 R&D 포트폴리오 바이오 천연물 유전자치료제 단백질 기능성소재 전문의약 DNA CAR T 항체사이토카인 piko ( 혈관 / 신경계질환 ) VM802 ( 혈액암 ) IE4 HX109 전립선비대증 HX210 ADHD 전임상연구 pmun ( 근육 / 신경계질환 ) VM803 ( 고형암 ) VM804 ( 고형암 ) 전임상연구 HX110 호흡기건강 HX111 불면증 임상개발 VM202 당뇨병성신경병증 ( 美임상 3 상 ) 당뇨병성족부궤양 ( 美임상 3 상 ) 루게릭병 ( 美임상 2 상 ) 심장병 ( 韓임상 2 상 ) VM501 항암보조요법 - 혈소판감소증 ( 中임상 3 상 ) 시장 PG102 HX106 유코믹스 레일라 VM206 유방암 ( 韓임상 1 상완료 ) HX111 #2

3 유전자치료제분류 유전자 직접주사 유전자전달체 세포이용 Cell/Gene Therapy - Naked plasmid DNA - Liposome - Electroporation AAV Adenovirus Retrovirus Vaccinia Herpesvirus 정상유전자 수정된유전자 새로운유전자 CAR-T CD34 기타세포 - Aptamer - RNAi Gene addition Gene replacement Gene editing #3

4 승인국가승인연도제품명회사명분류적응증 1 인당연간약가 미국 Luxturna (AAV) Spark 유전질환 RPE65 변이관련망막형성장애치료제 $ 850,000 ( 약 9 억 652 만원 ) 미국 Yescarta (CAR-T) Gilead (Kite) 암 B 세포비호지킨림프종 $ 373,000 ( 약 4 억 2 천만원 ) 미국 2017 Kymriah (CAR-T) Novartis 암 B- 세포유래급성림프구성백혈병 $ 475,000 ( 약 5 억 3,500 만원 ) 유럽 2016 Strimvelis (Retrovirus stem cell) GSK 유전질환 아데노신탈아미노효소결핍 (ADA-SCID) 600,000 ( 약 8 억원 ) 미국 2015 Imlygic (oncolytic virus) Amgen 암 절제불가능한악성흑색종 $ 65,000 ( 약 7,000 만원 ) 유럽 2012 Glybera UniQure 유전질환 지단백지질분해효소결핍증 (LPLD) 1,100,000 ( 약 15 억원 ) #4

5 총 21 개 암 (12 개 ), 유전질환 (4 개 ), 감염질환 (1 개 ), 만성질환 (4 개 ) 플라스미드 DNA 3 건 (2 건이바이로메드 ) 1 ViroMed 2 ViroMed 회사명적응증벡터 3 Vical & Astellas 만성질환 ( 당뇨병성신경병증 ) 만성질환 ( 당뇨병성궤양 ) 감염질환 (CMV 감염 ) 4 Advantagene 암 ( 전립선 ) DNA DNA DNA Vaccine HSV-TK/ Adenovirus 5 Advaxis 암 ( 자궁경부 ) HPV 6 Argos 암 ( 신장 ) RNA 7 Bluebird bio 8 Bluebird bio 9 BMS / Bavarian Nordic inc 유전질환 ( 대뇌부신백질이영양증 ) 유전질환 ( 베타지중해성빈혈 ) 암 ( 전립선 ) Lentivirus Lentivirus Poxvirus 10 FKD Therapies 암 ( 방광 ) Adenovirus 회사명적응증벡터 GenSight Biologics Guangzhou Double Bioproducts 유전질환 ( 레버시각신경병증 ) 암 ( 두경부 ) AAV Adenovirus 13 MolMed 암 ( 급성백혈병 ) Herpesvirus 14 Sillajen 암 ( 간 ) Vaccinia virus 15 Taxus Cardium 심장질환 ( 협심증 ) Adenovirus 16 Vascular Biogenics 암 ( 교모세포종 ) Adenovirus 17 TissueGene 퇴행성 ( 관절염 ) Retrovirus 18 Gilead / Kite 암 ( 외투세포림프종 ) CAR-T 19 Gilead / Kite 암 ( 비호지킨림프종 ) CAR-T 20 Celgene / bluebird bio 암 ( 다발성골수종 ) CAR-T 21 BioMarin 유전질환 ( 혈우병 ) AAV-factor VII #5

6 #6

7 현재바이로메드에서임상중인 DNA 의약 프로모터 5 UTR pck 치료유전자 1 HGF-X Intron Her2/Neu Her2/Neu (Ex+Tr) CD (Ex+Tr)CD IRES GM-CSF HGF 728 HGF 723 Her2/Neu (Ex+Tr) CD GM-CSF VM202 당뇨병성신경병증 당뇨병성허혈성궤양 근위축성측삭경화증 ( 루게릭병 ) 허혈성심장질환 ( 임상 2 상, 3 상 ) VM206 Her2 양성암 유방암 위암 기타 ( 임상 1 상완료 ) #7

8 바이로메드 DNA 의약플랫폼 특수제작된발현플랫폼에유전자를넣어다양한유전자치료제개발 발현플랫폼 (pck, ptx, pqx) 치료유전자 HGF Her2/neu SNI RTS X + Y VM202 VM206 piko pmun 연구 Cancer Vaccines Allergy #8

9 플라스미드 DNA 신제품 유전자 SNI 유전자 RTS 최적화 최적화 근육개선신경재생통증완화 PMUN pqx PIKO 상처치료 혈관형성 조직개선 신경 - 외상에의한신경손상 (Traumatic nerve injury) - 말초신경병증 (Peripheral neuropathy) - 길랭 - 바레증후군 (Guillain-Barre syndrome) 근육 - 좌골신경통 (Sciatica) - 근이영양증 (Muscular dystrophy) - 근력저하 (Muscle weakness) - 근육병 (Myopathy) - 샤르코 - 마리 - 투스병 (Charcot-Marie-Tooth) - 관상동맥질환 (Coronary artery disease) - 심근증 (Cardiomyopathy) - 만성창상 (Chronic wound) - 신경병증성통증 (Neuropathic pain) - 척수손상 (Spinal Cord Injury) - 말초동맥질환 (Peripheral arterial disease) - 동맥허혈궤양 (Ischemic ulcer) 혈관 - 근육감소증 (Sarcopenia) - 파행 (Claudication) - 심부전 (Heart failure) ( 목표 : 2025 년임상 3 상 ) #9

10 종배양발효세포파쇄정제및농축 DS 제형및충진 DP ( 원료의약품 ) 완제 #10

11 근육주사를통해손상된혈관과신경을재생시킬수있는혁신적인 DNA 의약 두종류의 HGF 단백질 (HGF 723, HGF 728 ) 을고효율로동시에생산하도록설계된플라스미드 DNA 특징 유전자발현수준매우높음 치료유전자 : HGF 두개이형체동시발현 동결건조 : 안정성제고 대량생산용이 #11

12 심혈관질환 척수 신경계질환 허혈성심장질환 심근경색증 한국임상 2 상 ( 진행중 ) 운동신경세포 근위축성측삭경화증 ( 루게릭병 ) 미국임상 2 상 ( 준비중 ) 근육 허혈성지체질환 중증하지허혈 (CLI) 당뇨병성허혈성궤양 미국임상 3 상 ( 진행중 ) 당뇨병성신경병증 통증성당뇨병성신경병증 미국임상 3 상 ( 진행중 ) #12

13 - 임상 3 상에서성공한다면 - 세계첫번째당뇨병성신경병증유전자치료제 세계첫번째 disease-modifying 신경병증치료제 세계첫번째당뇨병성족부궤양유전자치료제 세계첫번째 DNA 의약 #13

14 Strategy of clinical development for VM202 Phase III William K. Schmidt, PhD

15 VM202 Innovative Medicine for Major Indications with High Unmet Medical Needs #15

16 Flagship Product VM202 Innovative DNA medicine that induces formation of new blood vessels and repair damaged neurons following a simple series of IM injections Plasmid DNA designed to simultaneously express two isoforms of HGF Features High level gene expression in vivo Therapeutic gene: HGF Simultaneous expression of two isoforms of HGF Easy for bulk production Lyophilized: improved stability #16

17 #17 MOA of VM202 Spinal cord Sensory neuron Cell body 2. Pain Relief Degenerating axons Motor neuron Axon regeneration Reinnervation 3. Regeneration of peripheral nerve cells Muscle spindle HGF HGF NMJ 4. Amelioration of muscle atrophy I.M. injection (VM202) Skeletal muscle I.M. injection (VM202) 1. Angiogenesis

18 Clinical Development of VM202 Cardiovascular Coronary Artery Disease Acute Myocardial Infarction Phase II (Korea) ongoing Spinal Cord Neurological Amyotrophic Lateral Sclerosis Lou Gehrig s Disease Phase II (US) planned Motor neuron Spinal Cord Muscle Peripheral Artery Disease Chronic Non-Healing Foot Ulcer Phase III (US) ongoing Diabetic Peripheral Neuropathy Painful Diabetic Peripheral Neuropathy Phase III (US) ongoing #18

19 1 st Target Disease of VM202 Painful Diabetic Peripheral Neuropathy (PDPN) One of the most frequently observed neuropathies associated with 30% of all diabetes patients Patients suffer from sensory loss, dysesthesia, and night time pain. Hyperglycemia Painful diabetic peripheral neuropathy Blood vessel damage Nerves shrivel when blood vessels disappear Throbbing, Burning, Stabbing, Tingling Normal Blood vessel Nerve #19

20 Currently Used Medicines for Painful DPN There are 3 major drugs for DPN, generating $ 3-4 billion market. Anticonvulsant: Antidepressant: Opioid: NSAIDs Pregabalin (Lyrica, Pfizer) $ ~5.1 Billion (2014), Neuropathic pain market: 30-50% Duloxetine (Cymbalta, Eli Lilly) $ 5 Billion (2013), Neuropathic pain market: > $1 Billion Tapentadol (Nucynta ER, Depomed) Overall sales: $ 281 Million (US, 2016) FDA Approved for DPN Pain Treatment benefit modest Tolerability and side effects minimize compliance Several failed clinical trials in moderate to severe PDPN #20

21 Poor Tolerability of Current Medications for Painful DPN Outcome Efficacy outcomes Cumulative ranking for efficacy and tolerability Pregabalin (Lyrica) Gabapentin (Neurontin) Duloxetine (Cymbalta) 30% pain reduction % pain reduction Tolerability outcomes Somnolence Dizziness Nausea Headache Fatigue Constipation Diarrhea Discontinuation due to adverse events Meta-analysis of 25 published studies, ; van Nooten F, et al. Clin Ther #21

22 Potential Advantages of VM202 Administered only 2x in Phase II clinical trials (Day 0 and Day 14) Minimal discomfort from patterned i.m. injections High efficacy observed at 3 months (primary endpoint) that continues for months without further treatment Very high tolerability (minimal treatment-related adverse effects) Very high patient acceptability (PGIC = patient global impression of change) Potential disease-modifying drug (first-ever!) #22

23 Study Outline of VM202-DPN Phase II A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study (US, Korea) Principal Investigator JOHN (JACK) A. KESSLER, M.D. (Northwestern Medical School) 1. Indication: Painful Diabetic Peripheral Neuropathy 2. Total administered subjects: Injection scheme Bilateral 2 injection cycles along the calf line (day 0 & 14) (~ 2cm deep) (~ 2cm distance) 4. Follow-up period: 9 months 5. Efficacy Pain score (Daily Pain and Sleep Interference Diary)* VAS*, BPI-DPN*, MNSI, PGIC* and histological findings on skin biopsy * These methods were used in Pfizer s clinical studies for Lyrica. 6. Safety #23

24 Effect on Pain Severity (Daily Pain Diary) 2 Rounds of IM injection of VM202 2 Rounds of IM injection of VM202 Changes in severity from baseline * (Δ=-1.5) All Subjects (n=84) Months after first injection [*p<0.05, vs. placebo, p<0.05, vs. baseline, Δ VM202 16mg Placebo] (Δ=-1.19) (Δ=-1.03) Placebo VM mg (8 mg/leg) High long-term pain-relieving effects Data on other pain killers taken from public sources Changes in severity from baseline Subjects NOT on Lyrica and/or Neurontin (n=49) * (Δ=-2.37) (Δ=-2.29) (Δ=-1.47) Months after first injection [*p<0.05, vs. placebo, p<0.05, vs. baseline, Δ VM202 16mg Placebo] * Placebo VM mg (8 mg/leg) : Higher pain-relieving effects in subjects not on gabapentin and/or pregabalin #24

25 Data Suggesting VM202 s Potential to Become a Disease-Modifying Drug Effect of VM202 in Monofilament Test All Subjects (n=84) NOM = patients NOT taking Lyrica and/or Neurontin in the present study *p<0.05, vs. placebo group 9 months Placebo VM202 Left 13.3% 44.4% Right 25.0% 38.5% Both 19.4% 41.5% * NOM (n=49) Left 0% 56.3% Right 18.2% 57.2% Both 9.1% 56.7% Simplified from Kessler et al. Annals of Clinical and Translational Neurology, 2: (2015) The 16 mg group showed improvement in sensory threshold at 9 months. Again, patients not on Lyrica and/or Neurontin responded far better to VM202, for up to 9 months. * * #25

26 Key Discoveries of DPN Phase II Trial 1. VM202 has shown an excellent safety profile compared to current prescription drugs. (No antibody to HGF, No change in HGF serum level). 2. The 16 mg dose of VM202 (8 mg/leg) gave significant improvements in all pain measurements for a long period of time. (Daily pain diary, BPI-DPN, VAS, PGIC) 3. Pain relieving effects were more pronounced in patients who are not taking Lyrica and/or Neurontin. 4. Data from monofilament tests suggests that VM202 may aid recovery of sensory functions and has the potential to be a disease-modifying drug. #26

27 Study Outline of VM202-DPN Phase IIIs Double-Blind, Randomized, Placebo-Controlled, Multicenter Center Phase III-1 1. Target indication PDPN 2. Treatment arms 477 * (Placebo: 159, VM202: 318) Phase III-2 PDPN (not on gabapentin and/or pregabalin) 333 (Placebo: 111, VM202: 222) 3. Injection scheme 2 cycles 16 mg + 16 mg (Days 0, 14) (Days 90, 104) 4 cycles 16mg + 16mg + 16mg + 16mg (Days 0,14) (Days 90,104) (Days 180, 194) (Days 270, 284) 4. Follow-up 9 months 12 months 5. Primary endpoint Daily pain diary at 3 months, 50% responder at 3 months 6. Secondary endpoint Daily pain diary at 6 months 50% responder at 6 months 50% responder at 12 months Monofilament test at 12 months * 321 administered as of Jan 5, 2018 #27

28 VM202 Painful Diabetic Peripheral Neuropathy Current Phase III Clinical Trial Protocol VMDN-003 initiated November 10, 2016 Double-blind, randomized, placebo-controlled, multicenter, 9-month study Safety and efficacy of bilateral IM injection of VM202 in the calves of subjects with painful diabetic peripheral neuropathy (DPN) 16 mg of VM202 administered in divided doses at Day 0 and Day 14; second treatment of 16 mg VM202 at 3 months administered as divided doses at Day 90 and Day 104 Final total dose of 32 mg VM202 administered per subject Treatment - VM subjects Control - Placebo (VM202 vehicle) subjects Study Objectives: To evaluate the efficacy (relief of pain) and safety of IM administration of VM202 vs. placebo in subjects with painful DPN in the lower extremities #28

29 VM202 Painful Diabetic Peripheral Neuropathy Current Phase III Clinical Trial 25 geographically-distributed sites in the USA #29

30 VM202 Painful Diabetic Peripheral Neuropathy Current Phase III Clinical Trial Dosing: All subjects will receive sixteen (16) 0.5 ml injections of VM202 or placebo evenly distributed over each calf at each visit. VM202 vehicle is indistinguishable from reconstituted VM202. Neither subject nor clinician will be able to distinguish placebo from VM202. #30

31 2 nd Target Disease of VM202 Chronic, Non-Healing, Ischemic Foot Ulcers in Diabetes Patients Ischemic foot ulcers result from narrowing or blockage of peripheral arteries in the legs. Many diabetes patients suffer from chronic, non-healing foot ulcer. Blocked / Occluded Peripheral Artery Vessels Claudication Rest Pain Ulcer (Chronic) Gangrene Amputation Hyperglycemia Atherosclerosis Diabetes 26 million Peripheral Neuropathy 15 million Chronic Foot Ulcer 4.5 million CLI 0.85 million Peripheral Artery Disease 8.5 million Chronic Foot Ulcer CLI Critical Limb Ischemia Total Number ~ 4.5 Million ~ 0.85 Million Amputation 82, ,000 Medical Costs $ 9-13 Billion ~ $ 8 Billion #33

32 Phase II Trial for CLI as a POC model A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study (US, Korea) Principal Investigator EMERSON C. PERIN, M.D. (Stem Cell Center Texas Heart Institute) 1. Indication: Critical Limb Ischemia (Rutherford class 4 and 5) 2. Total administered subjects: 52 Placebo (0.9% normal saline): 11 subjects Low dose of VM202 (2 mg/visit): 21 subjects High dose of VM202 (4 mg/visit): 20 subjects 30/52 (57.6%) subjects had diabetes. 3. Injection scheme: 4 injection cycles along the calf line (days 0, 14, 28, & 42), unilateral IM injection 4. Follow-up period: 12 months 5. Efficacy 6. Safety #34

33 Substantial Healing Effects Observed in Ulcers Placebo (Screening) Placebo (Day 90) Group (Number of ulcers) Completely healed Improved 1) Low dose (Screening) Low dose (Day 365) Placebo (n = 9) 11% (1/9) 11% (1/9) Low dose (n = 27) 52% (14/27) * 70% (19/27) High dose (Screening) High dose (Day 365) High dose (n = 13) 62% (8/13) * 69% (9/13) * (Kibbe et al., Gene Therapy (2016) 1-7) 1) Reduction of ulcer area > 50% [* p < 0.05, vs. placebo (Fischer Exact Test)] A higher % of completely healed ulcers was observed in the high dose group during 12-month follow-up period. #35

34 Study Outline of VM202-PAD Phase III Double-Blind, Randomized, Placebo-Controlled, Multicenter 1. Indication: Chronic Non-Healing Ischemic Diabetic Foot Ulcers - Ulcer(s) on or around the foot area that are unresponsive to standard therapies and persist despite 4 weeks of appropriate care 2. Total administered subjects: mg VM202 + Standard Care: Placebo (VM202 vehicle) + Standard Care: 200 subjects 100 subjects 3. Injection scheme: 4 unilateral injection cycles in the ipsilateral calf of the affected foot (day 0, 14, 28, and 42) 4. Follow-up: 7 months 5. Efficacy endpoints: Primary: Complete wound closure, 4 months 6. Safety endpoints SilhouetteStar Ulcer size is measured using 3D camera to determine ulcer depth or volume #36

35 VM202 5-Year Timeline Partnership with global pharmaceuticals Two phase IIIs DPN, PAD BLA Current approval 1 st treatment DPN Phase III-1 Completion expected DPN Phase III-2 Completion expected approval 1 st treatment approval 1 st treatment PAD Phase III-1 Completion expected #37

36 Market estimation for PDPN Cathryn A. Carroll, PhD

37 ViroMed s Goal through 2025 Global Leader in DNA-Based Gene Therapy To be the only biotech company with world s largest revenue from gene therapies by 2025 Targeting major human diseases with high unmet medical needs Skills and expertise in clinical development Market competitiveness Cardiovascular diseases Neurovascular and neuromuscular diseases Muscular diseases Running two phase IIIs in the US for DPN* and NHU* Extensive clinical experience High safety of DNA drug Advanced technology * DPN: diabetic peripheral neuropathy * NHU: non-healing ischemic diabetic foot ulcer Highly prevalent diseases Current treatment methods: - Highly limited in efficacy & safety Disease modifying potential #39

38 Key Considerations to Be Competitive Differentiating VM202 (EASY) VM202 s Position in PDPN Market Drug Pricing Analysis To Date Target Patient Population & Peak Sales Estimates to Date 2018 Market Shaping Needs & Priorities #40

39 Differentiating VM202 Is Easy Overview of various pathogenetic components contributing to DPN. Kevin L. Farmer et al. Pharmacol Rev 2012;64: by The American Society for Pharmacology and Experimental Therapeutics #41

40 Know Competition Strengths & Weakness Anticonvulsants: Antidepressants: NSAIDs Opioids: Pregabalin (Lyrica, Pfizer) $ ~5.1 Billion (2014), Neuropathic pain market: 30-50% Gabapentin (Neurontin, Pfizer) $ ~ 210 Million (2014) Duloxetine (Cymbalta, Eli Lilly) $ 5 Billion (2013), Neuropathic pain market: > $1 Billion Tapentadol (Nucynta ER, Depomed) Overall sales: $ 281 Million (US, 2016) Treatment benefit (pain control) is modest No disease modifying potential, neuroregeneration or angiogenesis Act centrally with significant adverse effects including increased risk of suicidal thoughts or behavior, dizziness, sleepiness Several failed clinical trials in moderate to severe PDPN #42

41 Know VM202 s Expected Place In Therapy #43

42 Price Appropriately (Completed by Viewpoint Health November 2017) Key Attributes Results Indication & region PDPN in the USA Price Net of Discounts/Rebates $50,000 No. of treated patients ( ) for years Estimation period Peak revenue ($ Billion) Probability of Successful Commercialization 1,363, years $ % Discount rate 15% VM202-DPN risk-adjusted NPV ($ Billion) $14.1-$15.5 #44

43 Proactively Prepare the Market for Launch Differentiating VM202 Through An Innovative Linguistic Platform (Lexicon) Insight Gathering Telling the ViroMed & VM202 Story #45

44 Proactively Prepare the Market for Launch Shining The Light on Patient & Caregiver Needs Activating KOLs Surveillance on Distribution and Physician Adoption of Like Technologies #46

45 Key Considerations to Be Competitive It s Easy to Differentiate VM202 VM202 s Greatest Differentiation is in Individuals with Moderate to Severe PDPN Drug Pricing Analysis Will Continue Target Patient Population and Peak Sales Estimates to Date are Exciting Market Shaping Activities Are Under Way #47

46 ViroMed s Goal through 2025 Global Leader in DNA-Based Gene Therapy To be the only biotech company with world s largest revenue from gene therapies by 2025 Targeting major human diseases with high unmet medical needs Skills and expertise in clinical development Market competitiveness Cardiovascular diseases Neurovascular and neuromuscular diseases Muscular diseases Running two phase IIIs in the US for DPN* and NHU* Extensive clinical experience High safety of DNA drug Advanced technology * DPN: diabetic peripheral neuropathy * NHU: non-healing ischemic diabetic foot ulcer Highly prevalent diseases Current treatment methods: - Highly limited in efficacy & safety Disease modifying potential #48

기관고유연구사업결과보고

기관고유연구사업결과보고 기관고유연구사업결과보고 작성요령 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 2001 ~ 2004 2005 ~ 2007 2008 ~ 2010 1 2/3 2 1 0 2 3 52 0 31 83 12 6 3 21 593 404 304 1,301 4 3 1 8 159 191 116 466 6 11 (`1: (1: 16 33 44 106

More information

황지웅

황지웅 Comparison of Laparoscopy and Exploration in the Distal Pancreatectomy BACKGROUND: To determine the benefits of laparoscopic surgery compared with exploration, the clinical outcomes of open and laparoscopic

More information

Treatment and Role of Hormaonal Replaement Therapy

Treatment and Role of Hormaonal Replaement Therapy Treatment and Role of Hormone Replacement Therapy Chung-Ang University Hospital Chee Jeong Kim 7.2 5.3 6.4 5.6 7.3 5.5 1 1 2 3 4 10 11 7 34 49 122 123 1.0 - - 10. 2001 1998 1998 Improvement of postmenopausal

More information

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee University College of Medicine & Hospital E mail : ycell2@yahoo.co.kr Abstract

More information

00약제부봄호c03逞풚

00약제부봄호c03逞풚 경희대학교 동서신의학병원 약품 정보지 2 0 0 7. S P R I N G. V O L. 0 1 신약 소개 02 Journal Review 03 Special Subject 04 복약 지도 06 의약품 안전성 정보 07 약제부 알림 07 약제부 업무 소개 08 E A S T - W E S T N E O M E D I C A L C E N T E R 본 약품

More information

한국성인에서초기황반변성질환과 연관된위험요인연구

한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 한국성인에서초기황반변성질환과 연관된위험요인연구 - - i - - i - - ii - - iii - - iv - χ - v - - vi - - 1 - - 2 - - 3 - - 4 - 그림 1. 연구대상자선정도표 - 5 - - 6 - - 7 - - 8 - 그림 2. 연구의틀 χ - 9 - - 10 - - 11 -

More information

( )Jkstro011.hwp

( )Jkstro011.hwp 비인강암의방사선치료결과및생존율에관한예후인자분석 2005 2 1 2005 3 28. :, Tel: 053)250-7665, Fax: 053)250-7984 E-mail: jhkim@dsmc.or.kr 정영연외 2 인 : 비인강암의예후인자분석 정영연외 2 인 : 비인강암의예후인자분석 Carcinoma of the nasopharynx treated by radiotherapy

More information

歯1.PDF

歯1.PDF 200176 .,.,.,. 5... 1/2. /. / 2. . 293.33 (54.32%), 65.54(12.13%), / 53.80(9.96%), 25.60(4.74%), 5.22(0.97%). / 3 S (1997)14.59% (1971) 10%, (1977).5%~11.5%, (1986)

More information

A 617

A 617 Special Issue Diabetic Retinopathy Won Ki Lee, M.D. Department of Ophthalmology The Catholic University of Korea College of Medicine Kangnam St. Mary s Hospital E mail : wklee@catholic.ac.kr Abstract R

More information

( )Kju269.hwp

( )Kju269.hwp 만성세균성전립선염모델흰쥐에서 의항염효과 Anti-inflammatory Effect of Lycopene on Chronic Bacterial Prostatitis Rat Model Cho Hwan Yang, Dong Wan Sohn, Yong-Hyun Cho From the Department of Urology, The Catholic University

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA 27(2), 2007, 96-121 S ij k i POP j a i SEXR j i AGER j i BEDDAT j ij i j S ij S ij POP j SEXR j AGER j BEDDAT j k i a i i i L ij = S ij - S ij ---------- S ij S ij = k i POP j a i SEXR j i AGER j i BEDDAT

More information

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie Volume 12, Number 1, 92~102, An Intervention Study of Pain Reduction during IV Therapy in Hospitalized Children Myo-Jin Kim 1), Joung-Hae Bak 1), Won-Seok Seo 2) Mi-Young Kim 3), Sun-Kyoung Park 3), Jai-Soung

More information

슬라이드 1

슬라이드 1 혁신바이오신약의선도기업 바이로메드 바이로메드 ( 요약 ) 1. 설립일 : 1996.11.21 2. 코스닥상장 : 2005.12.29 (KOSDAQ: 084990) 3. 주식발행총수 : 13,699,201 4. 자본금 : 66.9억원 5. 주요사업분야 : 바이오신약, 천연물신약개발 6. 종업원수 : 60명 (R&D, 35명 ) 2 바이로메드 - 파이프라인 [

More information

원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현

원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현 원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현 원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현 원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 지도김석원교수 이논문을석사학위논문으로제출함

More information

Lumbar spine

Lumbar spine Lumbar spine CT 32 111 DOI : 10.3831/KPI.2010.13.2.111 Lumbar Spine CT 32 Received : 10. 05. 23 Revised : 10. 06. 04 Accepted : 10. 06. 11 Key Words: Disc herniation, CT scan, Clinical analysis The Clinical

More information

012임수진

012임수진 Received : 2012. 11. 27 Reviewed : 2012. 12. 10 Accepted : 2012. 12. 12 A Clinical Study on Effect of Electro-acupuncture Treatment for Low Back Pain and Radicular Pain in Patients Diagnosed with Lumbar

More information

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할

저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할 저작자표시 - 비영리 - 변경금지 2.0 대한민국 이용자는아래의조건을따르는경우에한하여자유롭게 이저작물을복제, 배포, 전송, 전시, 공연및방송할수있습니다. 다음과같은조건을따라야합니다 : 저작자표시. 귀하는원저작자를표시하여야합니다. 비영리. 귀하는이저작물을영리목적으로이용할수없습니다. 변경금지. 귀하는이저작물을개작, 변형또는가공할수없습니다. 귀하는, 이저작물의재이용이나배포의경우,

More information

1..

1.. Volume 12, Number 1, 6~16, Factors influencing consultation time and waiting time of ambulatory patients in a tertiary teaching hospital Jee-In Hwang College of Nursing Science, Kyung Hee University :

More information

- i - - ii - - iii - - iv - - v - - vi - - 1 - - 2 - - 3 - 1) 통계청고시제 2010-150 호 (2010.7.6 개정, 2011.1.1 시행 ) - 4 - 요양급여의적용기준및방법에관한세부사항에따른골밀도검사기준 (2007 년 11 월 1 일시행 ) - 5 - - 6 - - 7 - - 8 - - 9 - - 10 -

More information

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr May 10~12 2012 Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression from obesity to metabolic syndrome originates in the

More information

Ashtrax

Ashtrax 유전자치료제 2015 년정리및 2016 년전망 유승신 바이로메드 2016. 12 4 유전자치료란? Contents 유전자치료제의적용범위와실례 유전자치료제의발전과정과개발현황 요약 2 What is Gene Therapy? Experimental treatment that involves introducing genetic material into a person

More information

페링야간뇨소책자-내지-16

페링야간뇨소책자-내지-16 야간뇨의진단과치료 - 실제적접근 - Reference 1. Choo MS, Ku JH, Park CH et al. Prevalence of Nocturia in a Korean Population Aged 40 to 89 Years. Neurourol Urodyn 2008; 27:60-64. 2. Weiss JP. Prevalence

More information

- iii - - i - - ii - - iii - 국문요약 종합병원남자간호사가지각하는조직공정성 사회정체성과 조직시민행동과의관계 - iv - - v - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - α α α α - 15 - α α α α α α

More information

바이로메드 ( KQ) 미국최초의 CRISPR( 유전자가위 ) 임상시 험승인으로글로벌센티먼트개선 11 월 30 일 FDA 는 Editas 社의 IND 신청을승인함. 미국에서 3 세대유전 자가위를인체에적용하는첫임상이곧시작될것. 미국대표유전자 치료제업체들의주가는대

바이로메드 ( KQ) 미국최초의 CRISPR( 유전자가위 ) 임상시 험승인으로글로벌센티먼트개선 11 월 30 일 FDA 는 Editas 社의 IND 신청을승인함. 미국에서 3 세대유전 자가위를인체에적용하는첫임상이곧시작될것. 미국대표유전자 치료제업체들의주가는대 바이로메드 (084990.KQ) 미국최초의 CRISPR( 유전자가위 ) 임상시 험승인으로글로벌센티먼트개선 11 월 30 일 FDA 는 Editas 社의 IND 신청을승인함. 미국에서 3 세대유전 자가위를인체에적용하는첫임상이곧시작될것. 미국대표유전자 치료제업체들의주가는대부분상승. 동사에대한투자심리개선전망 미국최초의유전자가위임상시험승인 지난 11 월 30 일,

More information

노영남

노영남 Purpose: Delayed massive hemorrhages from pseudoaneurysm rupture of the peripancreatic large arteries, after pancreaticoduodenectomy, are fatal. We reviewed the clinical course and outcome of bleeding

More information

Microsoft PowerPoint - 발표자료(KSSiS 2016)

Microsoft PowerPoint - 발표자료(KSSiS 2016) Sang Jun Kim, MD, PhD Application of 3D Printing in the Orthotic Fields Hallux Valgus, Charcot Marie Tooth, ADL Kit, Foot Insole, Wrist Pain, Foot Drop Development of Automated Program for Ankle Foot Orthosis

More information

l l l l l l l l l Lee, Geon Kook None This project was designed to establish the Tumor Bank of National Cancer Center in 2000. From the first tumor sample in 2000, the total of tumor and tumor-related

More information

충북의대학술지 Chungbuk Med. J. Vol. 27. No. 1. 1~ Charcot-Marie-Tooth Disease 환자의마취 : 증례보고 신일동 1, 이진희 1, 박상희 1,2 * 책임저자 : 박상희, 충북청주시서원구충대로 1 번지, 충북대학교

충북의대학술지 Chungbuk Med. J. Vol. 27. No. 1. 1~ Charcot-Marie-Tooth Disease 환자의마취 : 증례보고 신일동 1, 이진희 1, 박상희 1,2 * 책임저자 : 박상희, 충북청주시서원구충대로 1 번지, 충북대학교 충북의대학술지 Chungbuk Med. J. Vol. 27. No. 1. 1~5 2017 Charcot-Marie-Tooth Disease 환자의마취 : 증례보고 신일동 1, 이진희 1, 박상희 1,2 * 책임저자 : 박상희, 충북청주시서원구충대로 1 번지, 충북대학교의과대학마취통증의학교실, 의학연구소 (28644), happycat19@hanmail.net

More information

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345])

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345]) Cardiovascular Disease in Metabolic Syndrome 김상현 보라매병원내과 서울대학교의과대학내과학교실 Contents Metabolic syndrome and Cardiovascular system CVD Mortality Coronary artery disease Heart failure Atrial fibrillation Management

More information

김범수

김범수 Analysis of Outcomes after Resection of Sarcomatous Hepatocellular Carcinoma Purpose: Sarcomatous hepatocellular carcinoma (HCC) is rare. Therefore, the clinicopathologic characteristics and prognosis

More information

Vol.259 C O N T E N T S M O N T H L Y P U B L I C F I N A N C E F O R U M

Vol.259 C O N T E N T S M O N T H L Y P U B L I C F I N A N C E F O R U M 2018.01 Vol.259 C O N T E N T S 02 06 28 61 69 99 104 120 M O N T H L Y P U B L I C F I N A N C E F O R U M 2 2018.1 3 4 2018.1 1) 2) 6 2018.1 3) 4) 7 5) 6) 7) 8) 8 2018.1 9 10 2018.1 11 2003.08 2005.08

More information

15_3oracle

15_3oracle Principal Consultant Corporate Management Team ( Oracle HRMS ) Agenda 1. Oracle Overview 2. HR Transformation 3. Oracle HRMS Initiatives 4. Oracle HRMS Model 5. Oracle HRMS System 6. Business Benefit 7.

More information

Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120: Sheu HM, et al., British J Dermatol 1997; 136:884-890 Kao JS, et al., J Invest Dermatol 03; 1:446-464 1 10 0 3 Day Normal MLE Lotion Lotion MLE Cream Cream 80 7 70 6 3 Day Normal MLE Lotion Lotion MLE

More information

untitled

untitled Case Report : Asan Medical Center Cardiac Rehabilitation AACVPR (http://www.aacvpr.org/) KACVPR (http://www.kacvpr.com/) Backgrounds PCI 2,395 consecutive patients in Minnesota (Mayo Clinic) Between1994

More information

슬라이드 1

슬라이드 1 혁신바이오신약의선도기업 바이로메드 바이로메드 ( 요약 ) 1. 설립일 : 1996.11.21 2. 코스닥상장 : 2005.12.29 (KASDAQ: 084990) 3. 주요사업분야 : 바이오신약, 천연물신약 4. 주요제품 : - 심혈관질환치료제 - 당뇨병성신경병증치료제 - 항암제 ( 항체항암치료제, 항암치료백신 ) - 항암보조제 ( 혈소판감소증치료제 ) -

More information

Abstract Musculoskeletal Symptoms and Related Factors for Nurses and Radiological Technologists Wearing a Lead Apron for Radiation Pro t e c t i o n Jung-Im Yoo, Jung-Wan Koo 1 ) Angio Unit, Team of Radiology,

More information

..........5-45..

..........5-45.. K O R E A C E N T E R S F O R D I S E A S E C O N T R O L & P R E V E N T I O N PHWR Vol. 5 No. 45 www.cdc.go.kr 2012 11 9 5 45 ISSN:2005-811X Monitoring of antimicrobial resistance on non-tertiary hospitals

More information

레이아웃 1

레이아웃 1 대한위장관기질종양연구회 01 GIST 06 02 11 03 Imatinib 14 04 05 06 07 Sunitinib 32 40 44 48 GIST 6 01 7 GIST Guide book GIST 8 01 9 GIST Guide book GIST (CT) MRI FDG-PET 10 02 11 GIST Guide book 12 02 (Imatinib)

More information

DBPIA-NURIMEDIA

DBPIA-NURIMEDIA The e-business Studies Volume 17, Number 4, August, 30, 2016:319~332 Received: 2016/07/28, Accepted: 2016/08/28 Revised: 2016/08/27, Published: 2016/08/30 [ABSTRACT] This paper examined what determina

More information

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re EMF Health Effect 2003 10 20 21-29 2-10 - - ( ) area spot measurement - - 1 (Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern

More information

975_983 특집-한규철, 정원호

975_983 특집-한규철, 정원호 Focused Issue of This Month Gyu Cheol an, MD Department of Otolaryngology ead & Neck Surgery, Gachon University of College Medicine E - mail : han@gilhospital.com Won-o Jung, MD Department of Otolaryngology

More information

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345])

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345]) 당뇨병환자에서항혈소판제사용 - 아스피린일차예방을중심으로 - 경희대학교강동경희대병원 황유철 말씀드릴내용 당뇨병및심혈관질환의역학 아스피린의심혈관질환 1차, 2차예방효과 아스피린부작용및용량에따른효과차이 당뇨병환자에서아스피린사용의적응증 사망원인순위, 2010 년 25.6% 통계청 심혈관질환에의한의료비추세 6 조 1400 억 국민건강보험공단, 2002-2009 Multidisciplinary

More information

°Ç°�°úÁúº´6-2È£

°Ç°�°úÁúº´6-2È£ K O R E A C E N T E R S F O R D I S E A S E C O N T R O L & P R E V E N T I O N PHWR Vol. 6 No. 2 www.cdc.go.kr 2013 1 11 6 2 ISSN:2005-811X Flavivirus surveillance in mosquitoes collected from the quarantine

More information

<283732372D3733312920B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A1283035292E687770>

<283732372D3733312920B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A1283035292E687770> 대한안과학회지 제 49 권 제 5 호 2008 J Korean Ophthalmol Soc 49(5):727-731, 2008 DOI : 10.3341/jkos.2008.49.5.727 다초점 소프트콘택트렌즈의 노안의 시력보정에 대한 유용성 평가 김현경 1 김효명 2 정성근 1 가톨릭대학교 의과대학 성모병원 안과학교실 1, 고려대학교 의과대학 안암병원 안과학교실

More information

04-다시_고속철도61~80p

04-다시_고속철도61~80p Approach for Value Improvement to Increase High-speed Railway Speed An effective way to develop a highly competitive system is to create a new market place that can create new values. Creating tools and

More information

16_이주용_155~163.hwp

16_이주용_155~163.hwp 사상체질의학회지 2008;20(2):155-163 J of Sasang Constitutional Medicine Vol. 20, No. 2, 2008:155-163 http://www.esasang.com 腦 梗 塞 으로 발생한 少 陽 人 半 身 舞 蹈 病 患 者 치험 1례 이주용 이한얼 한경수 안택원 Abstract 대전대학교 한의과대학 사상체질과 A Soyangin

More information

슬라이드 1

슬라이드 1 CJ 2007 CONTENTS 2006 CJ IR Presentation Overview 4 Non-performing Asset Company Profile Vision & Mission 4 4 - & 4-4 - & 4 - - - - ROE / EPS - - DreamWorks Animation Net Asset Value (NAV) Disclaimer IR

More information

<3136C1FD31C8A320C5EBC7D52E687770>

<3136C1FD31C8A320C5EBC7D52E687770> 고속도로건설에 따른 지역간 접근성 변화분석 A study on the impact of new highway construction on regional accessibility The purpose of this is to analyse the interregional accessibility changes due to highway construction.

More information

<C0C7B7CAC0C720BBE7C8B8C0FB20B1E2B4C9B0FA20BAAFC8AD5FC0CCC7F6BCDB2E687770>

<C0C7B7CAC0C720BBE7C8B8C0FB20B1E2B4C9B0FA20BAAFC8AD5FC0CCC7F6BCDB2E687770> ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ 儀 禮 의 社 會 的 機 能 과 變 化 李 顯 松 裵 花 玉 ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ

More information

2017.09 Vol.255 C O N T E N T S 02 06 26 58 63 78 99 104 116 120 122 M O N T H L Y P U B L I C F I N A N C E F O R U M 2 2017.9 3 4 2017.9 6 2017.9 7 8 2017.9 13 0 13 1,007 3 1,004 (100.0) (0.0) (100.0)

More information

590호(01-11)

590호(01-11) T H E K O R E A N D O C T O R S W E E K L Y www.docdocdoc.co.kr I N S I D E 38 3 5 6 7 10 13 28 29 30 31 38 41 42 2 Advertisement Government & Medicine 3 Government & Medicine 4 Government & Medicine Government

More information

untitled

untitled 제 1 세부과제 안전한 예방접종 실천을 위한 전략 및 교육, 홍보 자료 개발 제 1 장. 서 론 제 1 절. 연구의 필요성 국가적인 차원에서 예방접종 사업은 전염병 관리를 위한 가장 중요한 방역 사업 중 하나로, 대다수의 전염병 발생률은 각종 전염병의 백신이 나온 후로 현저히 감소하였으며, 인류 역사상 가장 많은 생명을 전염병으로부터 구원해주었다. 그러나,

More information

현대패션의 로맨틱 이미지에 관한 연구

현대패션의 로맨틱 이미지에 관한 연구 한지닥섬유제품의인체생리반응및쾌적성평가 임순 Evaluation of Thermal Physiological Responses and Comfort in Dox Fabric Soon Im Professor, Dept. of Fashion Industry, Incheon National University This study performed the evaluation

More information

Study on the Improvement of Management System through Analysis of golf semi- market: Focus on Physical Education Facility Act Ji-Myung Jung 1, Ju-Ho Park 2 *, & Youngdae Lee 3 1 Korea Institute of Sport

More information

#Ȳ¿ë¼®

#Ȳ¿ë¼® http://www.kbc.go.kr/ A B yk u δ = 2u k 1 = yk u = 0. 659 2nu k = 1 k k 1 n yk k Abstract Web Repertoire and Concentration Rate : Analysing Web Traffic Data Yong - Suk Hwang (Research

More information

°Ç°�°úÁúº´5-44È£ÃÖÁ¾

°Ç°�°úÁúº´5-44È£ÃÖÁ¾ K O R E A C E N T E R S F O R D I S E A S E C O N T R O L & P R E V E N T I O N PHWR Vol. 5 No. 44 www.cdc.go.kr/phwr 2012 11 2 5 44 ISSN:2005-811X Vector surveillance after elimination of lymphatic filariasis

More information

<C7C1B7A3C2F7C0CCC1EE20B4BABAF1C1EEB4CFBDBA20B7B1C4AA20BBE7B7CA5FBCADB9CEB1B35F28C3D6C1BE292E687770>

<C7C1B7A3C2F7C0CCC1EE20B4BABAF1C1EEB4CFBDBA20B7B1C4AA20BBE7B7CA5FBCADB9CEB1B35F28C3D6C1BE292E687770> Through proactively respond Franchise New business launching instance : Focus on the BEERBARKET s successful story of INTO FRANCHISE SYSTEMS, INC. 선행적 대응을 통한 프랜차이즈 뉴비즈니스 런칭 사례 : 인토외식산업의 맥주바켓 성공사례 MAXCESS

More information

Microsoft PowerPoint - Freebairn, John_ppt

Microsoft PowerPoint - Freebairn, John_ppt Tax Mix Change John Freebairn Outline General idea of a tax mix change Some detailed policy options Importance of casting assessment in the context of a small open economy Economic effects of a tax mix

More information

16(1)-3(국문)(p.40-45).fm

16(1)-3(국문)(p.40-45).fm w wz 16«1y Kor. J. Clin. Pharm., Vol. 16, No. 1. 2006 x w$btf3fqpsu'psn û w m w Department of Statistics, Chonnam National University Eunsik Park College of Natural Sciences, Chonnam National University

More information

http://www.kbc.go.kr/ Abstract Competition and Concentration in the Market for the Multichannel Video Programming G h e e - Young Noh ( P r o f e s s o, rschool of Communication,

More information

±³º¸¸®¾óÄÚ084-0122

±³º¸¸®¾óÄÚ084-0122 URL : www.kyoborealco.com 2008년 4/4분기 오피스 시장 보고서 Forth Quarter 2008 Office Market Report 서울특별시 성동구 도선동 286번지 Tel. 82 2 2290 4048 Fax. 82 2 2290 4099 URL : www.kyoborealco.com Profile Contents 02 03 05

More information

2011´ëÇпø2µµ 24p_0628

2011´ëÇпø2µµ 24p_0628 2011 Guide for U.S. Graduate School Admissions Table of Contents 02 03 04 05 06 08 09 10 11 13 15 21 LEADERS UHAK INTERNATIONAL STUDENTS SERVICE www.leadersuhak.com Leaders Uhak International Students

More information

WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disabi

WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disabi WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성 ( 황수경 ) ꌙ 127 노동정책연구 2004. 제 4 권제 2 호 pp.127~148 c 한국노동연구원 WHO 의새로운국제장애분류 (ICF) 에대한이해와기능적장애개념의필요성황수경 *, (disability)..,,. (WHO) 2001 ICF. ICF,.,.,,. (disability)

More information

슬라이드 1

슬라이드 1 ViroMed 바이로메드개요 1. 설립일 : 1996.11.21 2. 코스닥상장 : 2005.12.29 (KOSDAQ: 084990) 3. 주요사업분야 : 바이오신약, 천연물신약개발 4. 주식발행총수 : 14,195,822 5. 자본금 : 69억원 6. 임직원수 : ~60명 (R&D >~30명 ) 자체개발한원천특허에기초하여거대시장진입을목표로 미국, 중국등에서임상개발중인극소수국내바이오기업중하나

More information

11¹ÚÇý·É

11¹ÚÇý·É Journal of Fashion Business Vol. 6, No. 5, pp.125~135(2002) The Present State of E-Business according to the Establishment Year and the Sales Approach of Dongdaemun Clothing Market Park, Hea-Ryung* and

More information

03이경미(237~248)ok

03이경미(237~248)ok The recent (2001-2010) changes on temperature and precipitation related to normals (1971-2000) in Korea* Kyoungmi Lee** Hee-Jeong Baek*** ChunHo Cho**** Won-Tae Kwon*****. 61 (1971~2000) 10 (2001~2010).

More information

<31382D322D3420BDC5B1D4C8AF5FB3EDB9AE28C3D6C1BEBABB292E687770>

<31382D322D3420BDC5B1D4C8AF5FB3EDB9AE28C3D6C1BEBABB292E687770> 醫 史 學 제18권 제2호(통권 제35호) 2009년 12월 Korean J Med Hist 18ː57 72 18ː173-188 Dec. Dec. 2009 2009 C 大 韓 醫 史 學 會 ISSN ISSN 1225 505X 1225-505X 지방병 연구와 식민지배 : 1927년 영흥 및 해남지역 에메틴 중독사건을 중심으로 신 규 환* 1. 머리말 2. 일제의

More information

K O R E A C E N T E R S F O R D I S E A S E C O N T R O L & P R E V E N T I O N PHWR Vol. 5 No. 41 www.cdc.go.kr/phwr 2012 10 12 5 41 ISSN:2005-811X Comparison of drug-susceptibility test to the anti-tuberculosis

More information

` Companies need to play various roles as the network of supply chain gradually expands. Companies are required to form a supply chain with outsourcing or partnerships since a company can not

More information

Journal of Educational Innovation Research 2017, Vol. 27, No. 1, pp DOI: * The

Journal of Educational Innovation Research 2017, Vol. 27, No. 1, pp DOI:   * The Journal of Educational Innovation Research 2017, Vol. 27, No. 1, pp.243-268 DOI: http://dx.doi.org/10.21024/pnuedi.27.1.201703.243 * - 2001 2015 - The Research Trends on Peer Counseling in Elementary and

More information

ÀÇÇа�ÁÂc00Ì»óÀÏ˘

ÀÇÇа�ÁÂc00Ì»óÀÏ˘ Common Allergic Diseases in Children Sang - Il Lee, M.D. Department of pediatrics Sungkyunkwan University School of Medicine, Samsung Medical Center E - mail : silee@smc.samsung.co.kr Abstract Allergy

More information

04조남훈

04조남훈 Received : 2011. 11. 16 Reviewed : 2011. 11. 25 Accpeted : 2011. 12. 5 A Case Report of Prescribing Yanghyeolgeopung-tang(yangxuequfeng-tang) to Two Patients with Cervical Disc Herniation and Headache

More information

ePapyrus PDF Document

ePapyrus PDF Document Introduction 373 374 Definition of Child Abuse 375 376 Current Status of Child Abuse 377 378 Causes of Child Abuse 379 Signs and Sequelae of Child Abuse 380 A B C 381 382 383 384 385 Clinical Evaluation

More information

16(2)-7(p ).fm

16(2)-7(p ).fm w wz 16«2y Kor. J. Clin. Pharm., Vol. 16, No. 2. 2006 ü t xy y w tœ ½ BÁ x BC B y w w w C y w w w Current Status and Expectations of Orphan Drugs in Korea -In point of supplying medicines for the rare

More information

03±èÀçÈÖ¾ÈÁ¤ÅÂ

03±èÀçÈÖ¾ÈÁ¤Å x x x x Abstract The Advertising Effects of PPL in TV Dramas - Identificaiton by Implicit Memory-based Measures Kim, Jae - hwi(associate professor, Dept. of psychology, Chung-Ang University) Ahn,

More information

12이문규

12이문규 Review on Conservative Treatment of Spinal Scoliosis Moon-kyu Lee, O.M.D., Gil-jae Lee, O.M.D., Yun-kyung Song, O.M.D., Hyung-ho Lim, O.M.D. Dept. of Oriental Rehabilitation Medicine College of Oriental

More information

슬라이드 1

슬라이드 1 혁신바이오신약선도기업 바이로메드 바이로메드 ( 요약 ) 1. 설립일 : 1996.11.21 2. 코스닥상장 : 2005.12.29 (KOSDAQ: 084990) 3. 주요사업분야 : 바이오신약, 천연물신약개발 4. 주식발행총수 : 13,835,553 5. 자본금 : 66.9억원 6. 종업원수 : 60명 (R&D, 35명 ) 고유원천특허에기초하여선진국시장진입을목표로

More information

139~144 ¿À°ø¾àħ

139~144 ¿À°ø¾àħ 2 139 DOI : 10.3831/KPI.2010.13.2.139 2 Received : 10. 04. 08 Revised : 10. 04. 26 Two Case Report on Wrist Ganglion Treated with Scolopendrid Pharmacopuncture Accepted : 10. 05. 04 Key Words: Wrist Ganglion,

More information

Can032.hwp

Can032.hwp Chromosomal Alterations in Hepatocellular Carcinoma Cell Lines Detected by Comparative Genomic Hybridization Sang Jin Park 1, Mahn Joon Ha, Ph.D. 1, Hugh Chul Kim, M.D. 2 and Hyon Ju Kim, M.D. 1 1 Laboratory

More information

서론

서론 - i - - ii - - iii - - iv - - v - - vi - - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - -

More information

232 도시행정학보 제25집 제4호 I. 서 론 1. 연구의 배경 및 목적 사회가 다원화될수록 다양성과 복합성의 요소는 증가하게 된다. 도시의 발달은 사회의 다원 화와 밀접하게 관련되어 있기 때문에 현대화된 도시는 경제, 사회, 정치 등이 복합적으로 연 계되어 있어 특

232 도시행정학보 제25집 제4호 I. 서 론 1. 연구의 배경 및 목적 사회가 다원화될수록 다양성과 복합성의 요소는 증가하게 된다. 도시의 발달은 사회의 다원 화와 밀접하게 관련되어 있기 때문에 현대화된 도시는 경제, 사회, 정치 등이 복합적으로 연 계되어 있어 특 한국도시행정학회 도시행정학보 제25집 제4호 2012. 12 : pp.231~251 생활지향형 요소의 근린주거공간 분포특성 연구: 경기도 시 군을 중심으로* Spatial Distribution of Daily Life-Oriented Features in the Neighborhood: Focused on Municipalities of Gyeonggi Province

More information

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있 대한한방부인과학회지 THE JOURNAL OF ORIENTAL OBSTETRICS & GYNECOLOGY VOL.17, NO.2 : 115-122 (2004) 달생산이 초산모 분만시간에 미치는 영향 * 북경한의원, ** 윤산부인과의원, *** 최은림산부인과의원, 상지대학교 한의과대학 부인과학교실 ****, 경희대학교 동서의학대학원 김성준 *****, 윤왕준

More information

.,,,,,,.,,,,.,,,,,, (, 2011)..,,, (, 2009)., (, 2000;, 1993;,,, 1994;, 1995), () 65, 4 51, (,, ). 33, 4 30, (, 201

.,,,,,,.,,,,.,,,,,, (, 2011)..,,, (, 2009)., (, 2000;, 1993;,,, 1994;, 1995), () 65, 4 51, (,, ). 33, 4 30, (, 201 4 21.,,,.,,. 1, 2, 3, 4.,,,,,,.,,,,., ( ). 60-66,,,,,.. (Corresponding Author): / / 303 Tel: 063-220-2495/ E-mail: ikkim@jj.ac.kr .,,,,,,.,,,,.,,,,,, (, 2011)..,,, (, 2009)., (, 2000;, 1993;,,, 1994;,

More information

( ) Jkra076.hwp

( ) Jkra076.hwp Vol. 11, No. 4, December, 2004 Objective: Ultrasonography (USG) of joints has a unique position for the diagnosis of joint diseases. Bone surface, cartilage, periarticular soft tissue and their pathologic

More information

Journal of Educational Innovation Research 2017, Vol. 27, No. 2, pp DOI: : Researc

Journal of Educational Innovation Research 2017, Vol. 27, No. 2, pp DOI:   : Researc Journal of Educational Innovation Research 2017, Vol. 27, No. 2, pp.251-273 DOI: http://dx.doi.org/10.21024/pnuedi.27.2.201706.251 : 1997 2005 Research Trend Analysis on the Korean Alternative Education

More information

서론 34 2

서론 34 2 34 2 Journal of the Korean Society of Health Information and Health Statistics Volume 34, Number 2, 2009, pp. 165 176 165 진은희 A Study on Health related Action Rates of Dietary Guidelines and Pattern of

More information

Vol.257 C O N T E N T S M O N T H L Y P U B L I C F I N A N C E F O R U M

Vol.257 C O N T E N T S M O N T H L Y P U B L I C F I N A N C E F O R U M 2017.11 Vol.257 C O N T E N T S 02 06 38 52 69 82 141 146 154 M O N T H L Y P U B L I C F I N A N C E F O R U M 2 2017.11 3 4 2017.11 6 2017.11 1) 7 2) 22.7 19.7 87 193.2 160.6 83 22.2 18.4 83 189.6 156.2

More information

부속

부속 04 Definitions of terminology in neonatal, infant, and perinatal epidemiology.,. (perinatal period),,,, (morbidity) (mortality).,,,.,,,.,., 2. (World Health Organization, WHO) International Statistical

More information

00내지1번2번

00내지1번2번 www.keit.re.kr 2011. 11 Technology Level Evaluation ABSTRACT The Technology Level Evaluation assesses the current level of industrial technological development in Korea and identifies areas that are underdeveloped

More information

<BFA9BAD02DB0A1BBF3B1A4B0ED28C0CCBCF6B9FC2920B3BBC1F62E706466>

<BFA9BAD02DB0A1BBF3B1A4B0ED28C0CCBCF6B9FC2920B3BBC1F62E706466> 001 002 003 004 005 006 008 009 010 011 2010 013 I II III 014 IV V 2010 015 016 017 018 I. 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 037 038 039 040 III. 041 042 III. 043

More information

특수교육논총 * ,,,,..,..,, 76.7%.,,,.,,.. * 1. **

특수교육논총 * ,,,,..,..,, 76.7%.,,,.,,.. * 1. ** 특수교육논총 *. 257..,,,,..,..,, 76.7%.,,,.,,.. * 1. ** (eun67@dankook.ac.kr) .,,,,,,,,,, (,, 2014)., (,, 2007)....,,,, (,, 2014).. (2003)...,,, (Baron-Cohen, O Riordan, Stone, Jone, & Plaisted, 1999; Hobson,

More information

<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770>

<B0E6C8F1B4EBB3BBB0FA20C0D3BBF3B0ADC1C E687770> 심전도연수강좌 : 처음시작하는사람들을위한심전도 연세대학교원주의과대학순환기내과학교실 안민수 Cardiac Electrophysiology I : Automaticity : 60-100 회 /min, His bundle : 40-60 회 /min Bundle branch : 20-40 회 /min Purkinje fiber : 20 회 /min Cardiac Electrophysiology

More information

http://www.kbc.go.kr/pds/2.html Abstract Exploring the Relationship Between the Traditional Media Use and the Internet Use Mee-Eun Kang This study examines the relationship between

More information

±èÇö¿í Ãâ·Â

±èÇö¿í Ãâ·Â Smartphone Technical Trends and Security Technologies The smartphone market is increasing very rapidly due to the customer needs and industry trends with wireless carriers, device manufacturers, OS venders,

More information

석사논문.PDF

석사논문.PDF ABO Rh A study on the importance of ABO and Rh blood groups information in Public Health 2000 2 1 ABO Rh A study on the importance of ABO and Rh blood groups information in Public Health 2000 2 2 ABO Rh

More information

878 Yu Kim, Dongjae Kim 지막 용량수준까지도 멈춤 규칙이 만족되지 않아 시행이 종료되지 않는 경우에는 MTD의 추정이 불가 능하다는 단점이 있다. 최근 이 SM방법의 단점을 보완하기 위해 O Quigley 등 (1990)이 제안한 CRM(Continu

878 Yu Kim, Dongjae Kim 지막 용량수준까지도 멈춤 규칙이 만족되지 않아 시행이 종료되지 않는 경우에는 MTD의 추정이 불가 능하다는 단점이 있다. 최근 이 SM방법의 단점을 보완하기 위해 O Quigley 등 (1990)이 제안한 CRM(Continu 한 국 통 계 학 회 논 문 집 2012, 19권, 6호, 877 884 DOI: http://dx.doi.org/10.5351/ckss.2012.19.6.877 Maximum Tolerated Dose Estimation Applied Biased Coin Design in a Phase Ⅰ Clinical Trial Yu Kim a, Dongjae Kim

More information

07_Àü¼ºÅÂ_0922

07_Àü¼ºÅÂ_0922 176 177 1) 178 2) 3) 179 4) 180 5) 6) 7) 8) 9) 10) 181 11) 12) 182 13) 14) 15) 183 16) 184 185 186 17) 18) 19) 20) 21) 187 22) 23) 24) 25) 188 26) 27) 189 28) 29) 30)31) 32) 190 33) 34) 35) 36) 191 37)

More information

<B1B9C1A6B0B3B9DFC7F9B7C25FC3B9B0C9C0BD5FB3BBC1F62E706466>

<B1B9C1A6B0B3B9DFC7F9B7C25FC3B9B0C9C0BD5FB3BBC1F62E706466> I n t r o d u c t i o n t o I n t e r n a t i o n a l D e v e l o p m e n t C o o p e r a t i o n USD Billions (Current Prices) 600.00 500.00 400.00 300.00 355.5 421.2 476.4 597.7 480.0

More information

54 한국교육문제연구제 27 권 2 호, I. 1.,,,,,,, (, 1998). 14.2% 16.2% (, ), OECD (, ) % (, )., 2, 3. 3

54 한국교육문제연구제 27 권 2 호, I. 1.,,,,,,, (, 1998). 14.2% 16.2% (, ), OECD (, ) % (, )., 2, 3. 3 27 2, 53-70, 2009. (Nursing Home) * ** (Nursing Home). 5 50 5 2 1,,,,, SPSS t.,,,,,,,. :,, : 2009/08/27 : 2009/09/24 : 2009/09/30 * ** (: hjkim@daelim.ac.kr) 54 한국교육문제연구제 27 권 2 호, 2009. I. 1.,,,,,,, (,

More information

γ

γ 경락경혈학회지 Vol.27, No.1, pp.87 106, 2010 Journal of Meridian & Acupoint Dept. of 1 Meridian & Acupoint, 3 Acupuncture & Moxibustion, College of Oriental Medicine, Daejeon University 2 Division of Clinical

More information